#ESMO22: Amgen drops the detailed deck for KRAS G12C, with eroding data likely to trigger fresh debate
PARIS — Amgen put its best foot forward in Paris early Monday, with the news that its KRAS G12C star Lumakras offered a solid benefit for patients suffering from advanced cases of non-small cell lung cancer compared with chemo. The top-line figures included a drop of 34% in the risk of disease progression at 12 months in CodeBreaK 200, the confirmatory study being used for a near certain full approval.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.